203 related articles for article (PubMed ID: 18559972)
21. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
22. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
23. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Gu JJ; Santiago L; Mitchell BS
Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
[TBL] [Abstract][Full Text] [Related]
24. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
25. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
[TBL] [Abstract][Full Text] [Related]
26. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
27. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
28. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
29. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon NB; Gilliland DG; Druker BJ
Blood; 1997 Dec; 90(12):4947-52. PubMed ID: 9389713
[TBL] [Abstract][Full Text] [Related]
30. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
31. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Yu C; Dai Y; Dent P; Grant S
Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
[TBL] [Abstract][Full Text] [Related]
32. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
Tickenbrock L; Hehn S; Sargin B; Evers G; Ng PR; Choudhary C; Berdel WE; Müller-Tidow C; Serve H
Int J Hematol; 2008 Sep; 88(2):174-180. PubMed ID: 18668305
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
34. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
36. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
37. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Sausville EA
J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
[No Abstract] [Full Text] [Related]
38. Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
Papadopoulou LC; Kyriazou AV; Bonovolias ID; Tsiftsoglou AS
Blood Cells Mol Dis; 2014; 53(1-2):84-90. PubMed ID: 24726617
[TBL] [Abstract][Full Text] [Related]
39. Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells.
Li L; Zhang R; Fang ZY; Chen JN; Zhu ZL
J Int Med Res; 2009; 37(2):426-37. PubMed ID: 19383237
[TBL] [Abstract][Full Text] [Related]
40. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
